A previous study found the high ratio of CD3+/HLA-DR+ T cells, both on CD4+ helper and CD8+ cytotoxic T cells after chemotherapy, may predict the danger of relapse in patients with non-Hodgkin's lymphoma (41). This evidence concerns the gene CD4 and non-Hodgkin lymphoma.